Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Opioid use disorder (OUD) and schizophrenia are commonly comorbid, and patient outcomes are improved when these conditions are managed concurrently. Medication for OUD such as methadone and buprenorphine are treatments for OUD, yet psychosis introduces additional challenges in retaining patients in care. Extended-release depot buprenorphine is an emerging option for the treatment of moderate-to-severe OUD, and it may provide certain benefits in patients with concurrent OUD and psychosis. We present the case of a 32-year-old man with schizophrenia, traumatic brain injury, and OUD with a history of multiple opioid-related overdoses, followed by an assertive community treatment team, and subject to a community treatment order for both his primary psychotic disorder and OUD treatments. We discuss the role of extended-release depot buprenorphine in this unique patient population and the ethical considerations of involuntary treatment of OUD in patients lacking capacity to consent to treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ADM.0000000000001215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mortality during and following treatment with extended-release naltrexone based on data from two clinical trials.
Drug Alcohol Depend
September 2025
Department of Research and Development in Mental Health, Akershus University Hospital, Lørenskog, Norway; Norwegian Center for Addiction Research, SERAF, Faculty of Medicine, University of Oslo, Oslo, Norway; Vestfold Hospital Trust, Tønsberg, Norway.
Aims: To examine mortality during and in the first year following extended-release naltrexone (XR-NTX) treatment in patients with opioid use disorder (OUD).
Design: A prospective registry study.
Setting: Two clinical trials in Norway.
An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in systemic sclerosis-related Raynaud's phenomenon.
Rheumatology (Oxford)
May 2025
Clinical Development, Camurus AB, Lund, Sweden.
Objectives: Our aim was to explore the effect of a single subcutaneous dose of CAM2043, a novel extended-release subcutaneous formulation of treprostinil, on finger temperature in patients with systemic sclerosis (SSc)-related Raynaud's phenomenon (RP).
Methods: This was an exploratory, open-label, single-dose Phase 2 trial. Ten female patients (median age 54.
Monthly buprenorphine depot injection (SUBLOCADE®) for opioid use disorder during pregnancy.
Am J Addict
September 2025
Indivior Inc, North Chesterfield, Virginia, USA.
Background And Objectives: Untreated opioid use disorder (OUD) in pregnancy is associated with adverse obstetrical outcomes, maternal morbidity, and maternal mortality. This article will inform clinicians about the use of monthly extended-release buprenorphine (BUP-XR, SUBLOCADE®) to treat OUD during pregnancy and postpartum.
Methods: We examined the use of monthly BUP-XR during pregnancy in patients with OUD, summarizing case studies (N = 4) from clinical practice, reviewing >5 years of pregnancy and postpartum surveillance data (quantitative [N = 322] and qualitative) and relevant literature in PubMed (N = 4).
Understanding drug release mechanisms of risperidone in situ forming implant depots in rabbits.
J Control Release
July 2025
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA. Electronic address:
Injectable poly(lactic-co-glycolic acid) (PLGA)-based in situ forming implants are a promising long-acting drug delivery system. They are liquid formulations that solidify through solvent exchange to form drug-PLGA depots that become isolated from the surrounding tissue following injection. There have been limited studies focusing on in vivo drug release mechanisms for this dosage form.
View Article and Find Full Text PDFSurface-coated silica microparticles: In vitro and ex vivo evaluation of a preclinical extended release platform conceived for intravitreal injection.
J Control Release
May 2025
Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, 88397, Germany. Electronic address:
Current standard pharmacological treatment of retinal vascular diseases requires frequent intravitreal injection every 4-12 weeks. Active pharmaceutical ingredients (APIs) with better pharmacokinetics (PK), allowing less frequent administrations, remain to be discovered and developed. In preclinical stage mostly small molecule New Chemical Entities (NCEs) and peptides represent promising candidates.
View Article and Find Full Text PDF